Neuropathic Ocular Pain Market Expected to Experience Major Growth by 2034, According to DelveInsight | Novartis, OKYO Pharma, AbbVie Inc., Aciex Therapeutics, Novaliq, Oculeve and Allergan, Adverum

The Key Neuropathic Ocular Pain Companies in the market include - Aciex Therapeutics, Novaliq, Oculeve and Allergan, Adverum Biotechnologies and MeiraGTx, Ocular Therapeutix, Aldeyra Therapeutics, and others.

DelveInsight's "Neuropathic Ocular Pain Market Insights, Epidemiology, and Market Forecast-2034 report offers an in-depth understanding of the Neuropathic Ocular Pain, historical and forecasted epidemiology as well as the Neuropathic Ocular Pain market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

To Know in detail about the Neuropathic Ocular Pain market outlook, drug uptake, treatment scenario and epidemiology trends, Click here; Neuropathic Ocular Pain Market Forecast [https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Some of the key facts of the Neuropathic Ocular Pain Market Report:

*
The Neuropathic Ocular Pain market size is anticipated to grow with a significant CAGR of 5.2% during the study period (2020-2034)

*
In March 2025, OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company focused on developing novel treatments for neuropathic corneal pain and inflammatory dry eye disease, has submitted a Fast Track designation application to the U.S. Food and Drug Administration (FDA) for urcosimod (previously known as OK-101). The application targets neuropathic corneal pain-a chronic and severely painful eye condition impacting tens of thousands globally-with no currently approved FDA treatments available.

*
In October 2024, OKYO Pharma Limited (NASDAQ: OKYO), a clinical-stage biopharmaceutical company advancing innovative ocular treatments for inflammatory dry eye disease (DED) and neuropathic corneal pain (NCP)-a condition currently lacking FDA-approved therapies-has announced the start of patient screening and enrollment for a Phase 2 clinical trial of OK-101 for NCP. This 12-week, double-masked, randomized, placebo-controlled study will include 48 participants diagnosed with NCP, confirmed via confocal microscopy. The trial's primary objective is to evaluate pain reduction using the Visual Analog Scale (VAS).

*
In 2023, the total number of cases involving various eye disorders and surgeries across the 7MM reached approximately 18,465 thousand. This highlights the substantial impact of ocular conditions and emphasizes the growing need for medical care in these regions, pointing to key priorities for eye health management and treatment planning.

*
According to DelveInsight's analysis, Japan recorded approximately 3,352 thousand cases of various eye disorders in 2023. Of these, severe Dry Eye Disease accounted for 36%, post-operative complications made up 13%, cataract surgery cases represented 29%, and the remaining 21% were attributed to infections, systemic illnesses, and other ocular surface conditions.

*
In 2023, the EU4 and the UK together contributed around 1,625 thousand cases to the total number of Neuropathic Ocular Pain cases across the 7MM. Among these European nations, Italy reported the highest burden with approximately 535 thousand cases, followed by France with nearly 350 thousand cases.

*
DelveInsight's 2023 projections indicate that the EU4 and the UK represent 44% of the total cases related to various eye disorders and surgeries across the 7MM, exceeding the US at 38% and Japan at 18%. These figures are anticipated to increase throughout the forecast period from 2024 to 2034, suggesting a rising prevalence of these conditions.

*
Key Neuropathic Ocular Pain Companies: Aciex Therapeutics, Novaliq, Oculeve and Allergan, Adverum Biotechnologies and MeiraGTx, Ocular Therapeutix, Aldeyra Therapeutics, and others

*
Key Neuropathic Ocular Pain Therapies: Lidocaine, Ketamine, Nerve stimulation, Gene Therapy, Gabapentin, Pregabalin, and others

*
The Neuropathic Ocular Pain epidemiology based on gender analyzed that Neuropathic Ocular Pain (NOP) affects males and female equally

*
The Neuropathic Ocular Pain market is expected to surge due to the disease's increasing prevalence and awareness during the forecast period. Furthermore, launching various multiple-stage Neuropathic Ocular Pain pipeline products will significantly revolutionize the Neuropathic Ocular Pain market dynamics.

Neuropathic Ocular Pain Overview

Neuropathic ocular pain (NOP), also referred to as corneal neuropathic pain, is a condition in which corneal pain is seen in response to normally non-painful stimuli. This pain results from repeated direct damage to corneal nerves.

Get a Free sample for the Neuropathic Ocular Pain Market Report -

https://www.delveinsight.com/report-store/neuropathic-ocular-pain-nop-market [https://www.delveinsight.com/report-store/neuropathic-ocular-pain-nop-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Neuropathic Ocular Pain Epidemiology

The epidemiology section provides insights into the historical, current, and forecasted epidemiology trends in the seven major countries (7MM) from 2002 to 2034. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. The epidemiology section also provides a detailed analysis of the diagnosed patient pool and future trends.

Neuropathic Ocular Pain Epidemiology Segmentation:

The Neuropathic Ocular Pain market report proffers epidemiological analysis for the study period 2020-2034 in the 7MM segmented into:

*
Total Prevalence of Neuropathic Ocular Pain

*
Prevalent Cases of Neuropathic Ocular Pain by severity

*
Gender-specific Prevalence of Neuropathic Ocular Pain

*
Diagnosed Cases of Episodic and Chronic Neuropathic Ocular Pain

Download the report to understand which factors are driving Neuropathic Ocular Pain epidemiology trends @ Neuropathic Ocular Pain Epidemiology Forecast [https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Neuropathic Ocular Pain Drugs Uptake and Pipeline Development Activities

The drugs uptake section focuses on the rate of uptake of the potential drugs recently launched in the Neuropathic Ocular Pain market or expected to get launched during the study period. The analysis covers Neuropathic Ocular Pain market uptake by drugs, patient uptake by therapies, and sales of each drug.

Moreover, the therapeutics assessment section helps understand the drugs with the most rapid uptake and the reasons behind the maximal use of the drugs. Additionally, it compares the drugs based on market share.

The report also covers the Neuropathic Ocular Pain Pipeline Development Activities. It provides valuable insights about different therapeutic candidates in various stages and the key companies involved in developing targeted therapeutics. It also analyzes recent developments such as collaborations, acquisitions, mergers, licensing patent details, and other information for emerging therapies.

Neuropathic Ocular Pain Therapies and Key Companies

*
Lidocaine: Aciex Therapeutics

*
Ketamine: Novaliq

*
Nerve stimulation: Oculeve and Allergan

*
Gene Therapy: Adverum Biotechnologies and MeiraGTx

*
Gabapentin: Ocular Therapeutix

*
Pregabalin: Aldeyra Therapeutics

Discover more about therapies set to grab major Neuropathic Ocular Pain market share @ Neuropathic Ocular Pain Treatment Market [https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Scope of the Neuropathic Ocular Pain Market Report

*
Study Period: 2020-2034

*
Coverage: 7MM [The United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan]

*
Key Neuropathic Ocular Pain Companies: Aciex Therapeutics, Novaliq, Oculeve and Allergan, Adverum Biotechnologies and MeiraGTx, Ocular Therapeutix, Aldeyra Therapeutics, and others

*
Key Neuropathic Ocular Pain Therapies: Lidocaine, Ketamine, Nerve stimulation, Gene Therapy, Gabapentin, Pregabalin, and others

*
Neuropathic Ocular Pain Therapeutic Assessment: Neuropathic Ocular Pain current marketed and Neuropathic Ocular Pain emerging therapies

*
Neuropathic Ocular Pain Market Dynamics: Neuropathic Ocular Pain market drivers and Neuropathic Ocular Pain market barriers

*
Competitive Intelligence Analysis: SWOT analysis, PESTLE analysis, Porter's five forces, BCG Matrix, Market entry strategies

*
Neuropathic Ocular Pain Unmet Needs, KOL's views, Analyst's views, Neuropathic Ocular Pain Market Access and Reimbursement

To know more about Neuropathic Ocular Pain companies working in the treatment market, visit @ Neuropathic Ocular Pain Clinical Trials and Therapeutic Assessment [https://www.delveinsight.com/sample-request/neuropathic-ocular-pain-nop-market?utm_source=abnewswire&utm_medium=pressrelease&utm_campaign=gpr]

Table of Contents

1. Neuropathic Ocular Pain Market Report Introduction

2. Executive Summary for Neuropathic Ocular Pain

3. SWOT analysis of Neuropathic Ocular Pain

4. Neuropathic Ocular Pain Patient Share (%) Overview at a Glance

5. Neuropathic Ocular Pain Market Overview at a Glance

6. Neuropathic Ocular Pain Disease Background and Overview

7. Neuropathic Ocular Pain Epidemiology and Patient Population

8. Country-Specific Patient Population of Neuropathic Ocular Pain

9. Neuropathic Ocular Pain Current Treatment and Medical Practices

10. Neuropathic Ocular Pain Unmet Needs

11. Neuropathic Ocular Pain Emerging Therapies

12. Neuropathic Ocular Pain Market Outlook

13. Country-Wise Neuropathic Ocular Pain Market Analysis (2020-2034)

14. Neuropathic Ocular Pain Market Access and Reimbursement of Therapies

15. Neuropathic Ocular Pain Market Drivers

16. Neuropathic Ocular Pain Market Barriers

17. Neuropathic Ocular Pain Appendix

18. Neuropathic Ocular Pain Report Methodology

19. DelveInsight Capabilities

20. Disclaimer

21. About DelveInsight

About DelveInsight

DelveInsight is a leading Healthcare Business Consultant, and Market Research firm focused exclusively on life sciences. It supports Pharma companies by providing comprehensive end-to-end solutions to improve their performance.

It also offers Healthcare Consulting Services, which benefits in market analysis to accelerate the business growth and overcome challenges with a practical approach.

Media Contact
Company Name: DelveInsight
Contact Person: Gaurav Bora
Email:Send Email [https://www.abnewswire.com/email_contact_us.php?pr=neuropathic-ocular-pain-market-expected-to-experience-major-growth-by-2034-according-to-delveinsight-novartis-okyo-pharma-abbvie-inc-aciex-therapeutics-novaliq-oculeve-and-allergan-adverum]
Phone: +14699457679
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: NV
Country: United States
Website: https://www.delveinsight.com/

Legal Disclaimer: Information contained on this page is provided by an independent third-party content provider. ABNewswire makes no warranties or responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you are affiliated with this article or have any complaints or copyright issues related to this article and would like it to be removed, please contact retract@swscontact.com



This release was published on openPR.